Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 4
Submit an article Journal homepage
1,418
Views
8
CrossRef citations to date
0
Altmetric
Letter to the Editor

Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies

Andres Forero-TorresUniversity of Alabama at Birmingham, Birmingham, AL, USACorrespondence[email protected]
,
Nancy L. BartlettWashington University School of Medicine, St. Louis, MO, USA
,
Robert B. BerrymanBaylor University Medical Center, Dallas, TX, USA
,
Robert ChenCity of Hope National Medical Center, Duarte, CA, USA
,
Jeffrey V. MatousColorado Blood Cancer Institute, Denver, CO, USA
,
Michelle A. FanaleUniversity of Texas M. D. Anderson Cancer Center, Houston, TX, USA
,
Owen A. O'ConnorColumbia University Medical Center, New York Presbyterian Hospital, New York City, NY, USA
,
Randal OlshefskiNationwide Children's Hospital, Columbus, OH, USA
,
Scott E. SmithLoyola University Medical Center, Maywood, IL, USA
,
Dirk HuebnerTakeda Pharmaceuticals International Co., Cambridge, MA, USA
,
Pamela L. LevineSeattle Genetics, Inc., Bothell, WA, USA
,
Laurie E. GroveSeattle Genetics, Inc., Bothell, WA, USA
&
Ajay K. GopalUniversity of Washington Medical Center, Seattle, WA, USA
 show all
Pages 1151-1153 | Received 14 Mar 2014, Accepted 27 Jul 2014, Published online: 07 Oct 2014

References

  • Connors JM. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol 2005;23:6400–6408.
  • Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496–5504.
  • Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 2013;31:684–691.
  • Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009;27:805–811.
  • Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 2011;365:203–212.
  • Moskowitz CH, Kewalramani T, Nimer SD, et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004;124:645–652.
  • Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005;16:625–633.
  • Horning S, Fanale M, de Vos S, et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort. Ann Oncol 2008;19:118.
  • Wilson WH, Bryant G, Bates S, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993;11:1573–1582.
  • Cabanillas F, Rodriguez MA. MINE-ESHAP salvage therapy for recurrent and refractory lymphomas. Semin Hematol 1994;31:30.
  • Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP—an effective chemotherapy regimen in refractory and relapsing lymphoma:a 4-year follow-up study. J Clin Oncol 1994;12:1169–1176.
  • Hertzberg MS, Crombie C, Benson W, et al. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma. Ann Oncol 2006;17(Suppl. 4):iv25–iv30.
  • Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large- cell lymphoma:results of a phase II study. J Clin Oncol 2012;30: 2190–2196.
  • Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183–2189.
  • Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.